299 related articles for article (PubMed ID: 22131389)
21. Measurement of estrone-3-glucuronide and pregnanediol-3 alpha-glucuronide in early morning urine samples to monitor ovarian function.
Magini A; Pinzani P; Bolelli GF; Bassi F; Salerno R; Messeri G; Pazzagli M
J Biolumin Chemilumin; 1989 Jul; 4(1):567-74. PubMed ID: 2801241
[TBL] [Abstract][Full Text] [Related]
22. Prediction of ovulation with the assessment of LH and the E1G/P2G ratio in urinary samples.
Baviera G; Carroccio G; Scurria L; Pizzi V; Scarselli G
Acta Eur Fertil; 1988; 19(3):139-42. PubMed ID: 3067480
[TBL] [Abstract][Full Text] [Related]
23. Origins and consequences of the elongation of the human menstrual cycle during the menopausal transition: the FREEDOM Study.
Miro F; Parker SW; Aspinall LJ; Coley J; Perry PW; Ellis JE;
J Clin Endocrinol Metab; 2004 Oct; 89(10):4910-5. PubMed ID: 15472184
[TBL] [Abstract][Full Text] [Related]
24. Postpartum return of ovarian activity in nonbreastfeeding women monitored by urinary assays.
Gray RH; Campbell OM; Zacur HA; Labbok MH; MacRae SL
J Clin Endocrinol Metab; 1987 Apr; 64(4):645-50. PubMed ID: 3818896
[TBL] [Abstract][Full Text] [Related]
25. Use of urinary pregnanediol 3-glucuronide to confirm ovulation.
Ecochard R; Leiva R; Bouchard T; Boehringer H; Direito A; Mariani A; Fehring R
Steroids; 2013 Oct; 78(10):1035-40. PubMed ID: 23831784
[TBL] [Abstract][Full Text] [Related]
26. Mean versus individual hormonal profiles in the menstrual cycle.
Alliende ME
Fertil Steril; 2002 Jul; 78(1):90-5. PubMed ID: 12095496
[TBL] [Abstract][Full Text] [Related]
27. Algorithms with Area under the Curve for Daily Urinary Estrone-3-Glucuronide and Pregnanediol-3-Glucuronide to Signal the Transition to the Luteal Phase.
Usala SJ; Alliende ME; Trindade AA
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056427
[No Abstract] [Full Text] [Related]
28. Urinary ovarian and gonadotropin hormone levels in premenopausal women with low bone mass.
Sowers M; Randolph JF; Crutchfield M; Jannausch ML; Shapiro B; Zhang B; La Pietra M
J Bone Miner Res; 1998 Jul; 13(7):1191-202. PubMed ID: 9661084
[TBL] [Abstract][Full Text] [Related]
29. Female cancer survivors exposed to alkylating-agent chemotherapy have unique reproductive hormone profiles.
Johnson L; Sammel MD; Schanne A; Lechtenberg L; Prewitt M; Gracia C
Fertil Steril; 2016 Dec; 106(7):1793-1799.e2. PubMed ID: 27666565
[TBL] [Abstract][Full Text] [Related]
30. A pilot study on the utility of reduced urine collection frequency protocols for the assessment of reproductive hormones in adolescent girls.
Allaway HCM; John EM; Keegan TH; De Souza MJ
J Pediatr Endocrinol Metab; 2017 Oct; 30(10):1083-1093. PubMed ID: 28949930
[TBL] [Abstract][Full Text] [Related]
31. The development of over-the-counter (OTC) assays for pregnanediol-3-glucuronide and estrone-B,D-glucuronide.
Bahar I
Prog Clin Biol Res; 1988; 285():139-51. PubMed ID: 3231643
[TBL] [Abstract][Full Text] [Related]
32. Feasibility of using paper impregnated with urine instead of liquid urine for assessing ovarian activity.
Wasalathanthri S; Tennekoon KH; Sufi S
Ceylon Med J; 2003 Mar; 48(1):4-6. PubMed ID: 12795010
[TBL] [Abstract][Full Text] [Related]
33. Definition of the potentially fertile period from urinary steroid excretion rates. Part II. A threshold value for pregnanediol glucuronide as a marker for the end of the potentially fertile period in the human menstrual cycle.
Blackwell LF; Brown JB; Cooke D
Steroids; 1998 Jan; 63(1):5-13. PubMed ID: 9437789
[TBL] [Abstract][Full Text] [Related]
34. Reductions in urinary collection frequency for assessment of reproductive hormones provide physiologically representative exposure and mean concentrations when compared with daily collection.
Allaway HC; Williams NI; Mallinson RJ; Koehler K; De Souza MJ
Am J Hum Biol; 2015; 27(3):358-71. PubMed ID: 25353669
[TBL] [Abstract][Full Text] [Related]
35. The effect of small doses of progesterone released from two types of vaginal rings on ovarian activity and bleeding patterns during the first postpartum year.
Landgren BM; Jonsson B; Cekan SZ
Contraception; 1995 Apr; 51(4):255-60. PubMed ID: 7796592
[TBL] [Abstract][Full Text] [Related]
36. Direct radioimmunoassay of urinary estrogen and pregnanediol glucuronides during the menstrual cycle.
Stanczyk FZ; Miyakawa I; Goebelsmann U
Am J Obstet Gynecol; 1980 Jun; 137(4):443-50. PubMed ID: 7386528
[TBL] [Abstract][Full Text] [Related]
37. Establishing a Gold Standard for Quantitative Menstrual Cycle Monitoring.
Bouchard T; Yong P; Doyle-Baker P
Medicina (Kaunas); 2023 Aug; 59(9):. PubMed ID: 37763632
[No Abstract] [Full Text] [Related]
38. Monitoring reproductive aging in a 5-year prospective study: aggregate and individual changes in steroid hormones and menstrual cycle lengths with age.
Ferrell RJ; O'Connor KA; RodrÃguez G; Gorrindo T; Holman DJ; Brindle E; Miller RC; Schechter DE; Korshalla L; Simon JA; Mansfield PK; Wood JW; Weinstein M
Menopause; 2005; 12(5):567-77. PubMed ID: 16145311
[TBL] [Abstract][Full Text] [Related]
39. Using an ovarian monitor as an adjunct to natural family planning.
Cavero C
J Nurse Midwifery; 1995; 40(3):269-76. PubMed ID: 7798132
[TBL] [Abstract][Full Text] [Related]
40. Determination of ovarian function using first morning urine steroid assays.
Denari JH; Farinati Z; Casas PR; Oliva A
Obstet Gynecol; 1981 Jul; 58(1):5-9. PubMed ID: 7195531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
